The ultra-rare disease treatment Ilaris has finally passed the final hurdle to its reimbursement in Korea.

Novartis Korea recently completed drug price negotiations with the National Health Insurance Service for Ilaris (canakinumab), a treatment for hereditary periodic fever syndrome.

The company was quick to accept the conditional benefit decision from the National Health Insurance Review and Assessment Service's Drug Reimbursement Evaluation Committee in April, and quickly finalized what was expected to be a difficult drug price negotiation process. Novartis' determination for reimbursement is notable.

The company resubmitted the application and received a re-deliberatio